Research and Markets: PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/57dj8v/pharmapoint) has announced the addition of the "PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis to 2023" report to their offering.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.

The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

The drivers of growth in this market include the increasing RA patient population and the universal healthcare system, as well as the use of technology to connect patients with physicians and speed the process of diagnosis and treatment. Barriers to the growth of the market include government measures to cut healthcare spending, similar to the austerity measures implemented in the 5EU. In the RA market in Australia, there are a number of different treatment options available, similar to the 7MM.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

3.3 Prognosis

3.4 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.2 Australia

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Major Brands

5.2.1 Enbrel (etanercept)

5.2.2 Humira (adalimumab)

5.2.3 Remicade (infliximab)

5.2.4 Simponi (golimumab)

5.2.5 Cimzia (certolizumab pegol)

5.2.6 Orencia (abatacept)

5.2.7 Actemra/RoActemra (tocilizumab)

5.2.8 Rituxan/MabThera (rituximab)

5.2.9 Inflectra/Remsima (infliximab biosimilar)

5.2.10 Methotrexate (Numerous Brands)

5.3 Biosimilars

5.3.1 Introduction

5.3.2 Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases

5.3.3 Biosimilars in the Immunology Community

5.3.4 By the Numbers: Biosimilars in Development

5.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

5.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market

5.4 Other Therapies

6 Unmet Need and Opportunity

6.1 Overview

6.2 Development of Cost-Effective Therapies

6.3 Biomarkers to Predict Responsiveness to Therapy

6.4 Early Diagnosis of RA

6.5 Personalized Treatment Approach

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

7.2.1 Sarilumab

7.2.2 Sirukumab

7.2.3 Baricitinib

7.2.4 Filgotinib

7.2.5 RAVAX

7.3 Other Drugs in Development

8 Market Outlook

8.1 Drivers and Barriers - Global Issues

8.1.1 Driver: Launch of novel drugs, including oral JAK inhibitors and novel biologics for RA

8.1.2 Driver: Earlier diagnosis and treatment

8.1.3 Driver: Market entry of biosimilars will bring a therapy option for those who cannot afford branded biologics

8.1.4 Driver: Aging population and increasing prevalent cases of RA

8.1.5 Barrier: Efforts to reduce costs in the treatment of RA

8.1.6 Barrier: Lack of regulatory guidelines for biosimilars will delay their availability in some regions

8.1.7 Barrier: Entry of biosimilars will create a less expensive treatment alternative

9 Appendix

For more information visit http://www.researchandmarkets.com/research/57dj8v/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders